Dr. Reddy’s Laboratories Ltd ADR (RDY) - Net Assets

Latest as of September 2025: $362.08 Billion USD

Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has net assets worth $362.08 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($542.00 Billion) and total liabilities ($179.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RDY asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $362.08 Billion
% of Total Assets 66.8%
Annual Growth Rate 38.4%
5-Year Change 14144.3%
10-Year Change 162.72%
Growth Volatility 1817.82

Dr. Reddy’s Laboratories Ltd ADR - Net Assets Trend (2000–2025)

This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's net assets have evolved over time, based on quarterly financial data. Also explore RDY current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)

The table below shows the annual net assets of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. For live valuation and market cap data, see Dr. Reddy’s Laboratories Ltd ADR market capitalisation.

Year Net Assets Change
2025-03-31 $337.17 Billion +20.18%
2024-03-31 $280.55 Billion +21.45%
2023-03-31 $230.99 Billion +21.24%
2022-03-31 $190.53 Billion +7949.22%
2021-03-31 $2.37 Billion +15.54%
2020-03-31 $2.05 Billion -98.54%
2019-03-31 $140.20 Billion +10.86%
2018-03-31 $126.46 Billion +1.95%
2017-03-31 $124.04 Billion -3.34%
2016-03-31 $128.34 Billion +15.30%
2015-03-31 $111.30 Billion +22.58%
2014-03-31 $90.80 Billion -87.58%
2013-03-31 $731.04 Billion +1172.62%
2012-03-31 $57.44 Billion +24.91%
2011-03-31 $45.99 Billion +7.17%
2010-03-31 $42.91 Billion +2.07%
2009-03-31 $42.05 Billion -10.67%
2008-03-31 $47.07 Billion +12.90%
2007-03-31 $41.69 Billion +87.18%
2006-03-31 $22.27 Billion +6.29%
2005-03-31 $20.95 Billion -0.63%
2004-03-31 $21.08 Billion +12.29%
2003-03-31 $18.78 Billion +21.61%
2002-03-31 $15.44 Billion +194.81%
2001-03-31 $5.24 Billion +5144.25%
2000-03-31 $99.87 Million --

Equity Component Analysis

This analysis shows how different components contribute to Dr. Reddy’s Laboratories Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 549554.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings $315.79 Billion 94.72%
Common Stock $834.00 Million 0.25%
Other Comprehensive Income $3.98 Billion 1.19%
Other Components $12.78 Billion 3.83%
Total Equity $333.39 Billion 100.00%

Dr. Reddy’s Laboratories Ltd ADR Competitors by Market Cap

The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their market capitalization.

Company Market Cap
Korea Aerospace Industries
KO:047810
 $11.16 Billion
TMX Group Limited
TO:X
 $11.16 Billion
Industrivarden AB ser. C
ST:INDU-C
 $11.17 Billion
LPP S.A.
WAR:LPP
 $11.18 Billion
Kerry Group
IR:KRZ
 $11.15 Billion
TELECOM ITALIA ADR 1
F:TQIA
 $11.15 Billion
Pinnacle West Capital Corp
NYSE:PNW
 $11.14 Billion
Summit Therapeutics PLC
NASDAQ:SMMT
 $11.14 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Dr. Reddy’s Laboratories Ltd ADR's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 280,550,000,000 to 333,388,000,000, a change of 52,838,000,000 (18.8%).
  • Net income of 56,544,000,000 contributed positively to equity growth.
  • Dividend payments of 6,662,000,000 reduced retained earnings.
  • Share repurchases of 1,389,000,000 reduced equity.
  • New share issuances of 193,000,000 increased equity.
  • Other comprehensive income increased equity by 3,326,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $56.54 Billion +16.96%
Dividends Paid $6.66 Billion -2.0%
Share Repurchases $1.39 Billion -0.42%
Share Issuances $193.00 Million +0.06%
Other Comprehensive Income $3.33 Billion +1.0%
Other Changes $826.00 Million +0.25%
Total Change $- 18.83%

Book Value vs Market Value Analysis

This analysis compares Dr. Reddy’s Laboratories Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.03x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.64x to 0.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-03-31 $8.26 $13.58 x
2002-03-31 $20.28 $13.58 x
2003-03-31 $24.54 $13.58 x
2004-03-31 $27.54 $13.58 x
2005-03-31 $27.37 $13.58 x
2006-03-31 $0.65 $13.58 x
2007-03-31 $52.34 $13.58 x
2008-03-31 $55.80 $13.58 x
2009-03-31 $49.95 $13.58 x
2010-03-31 $50.60 $13.58 x
2011-03-31 $54.12 $13.58 x
2012-03-31 $67.51 $13.58 x
2013-03-31 $857.64 $13.58 x
2014-03-31 $106.39 $13.58 x
2015-03-31 $130.23 $13.58 x
2016-03-31 $150.04 $13.58 x
2017-03-31 $148.56 $13.58 x
2018-03-31 $152.19 $13.58 x
2019-03-31 $168.71 $13.58 x
2020-03-31 $2.47 $13.58 x
2021-03-31 $2.85 $13.58 x
2022-03-31 $229.08 $13.58 x
2023-03-31 $277.66 $13.58 x
2024-03-31 $336.58 $13.58 x
2025-03-31 $399.60 $13.58 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Dr. Reddy’s Laboratories Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 16.96%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 17.37%
  • • Asset Turnover: 0.66x
  • • Equity Multiplier: 1.48x
  • Recent ROE (16.96%) is below the historical average (61.98%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 13.86% 12.24% 0.73x 1.56x $3.86 Million
2001 14.16% 6.76% 0.92x 2.27x $217.13 Million
2002 31.84% 29.60% 0.88x 1.23x $3.37 Billion
2003 18.76% 19.55% 0.78x 1.23x $1.64 Billion
2004 11.76% 12.32% 0.75x 1.27x $371.02 Million
2005 1.01% 1.08% 0.66x 1.40x $-1.88 Billion
2006 326.15% 6.71% 0.35x 137.34x $1.58 Billion
2007 22.43% 14.33% 0.76x 2.07x $5.18 Billion
2008 9.94% 9.36% 0.59x 1.82x $-28.62 Million
2009 -12.29% -7.44% 0.83x 1.99x $-9.37 Billion
2010 2.49% 1.52% 0.87x 1.87x $-3.22 Billion
2011 24.01% 14.78% 0.79x 2.07x $6.44 Billion
2012 24.83% 14.74% 0.81x 2.08x $8.52 Billion
2013 2.30% 14.43% 0.08x 1.95x $-56.31 Billion
2014 23.69% 16.28% 0.78x 1.87x $12.43 Billion
2015 19.93% 14.97% 0.76x 1.75x $11.05 Billion
2016 15.59% 12.94% 0.75x 1.62x $7.18 Billion
2017 9.71% 8.55% 0.64x 1.77x $-365.40 Million
2018 7.75% 6.90% 0.63x 1.78x $-2.84 Billion
2019 13.41% 12.22% 0.68x 1.61x $4.78 Billion
2020 951.72% 11.17% 56.88x 1.50x $19.29 Billion
2021 9.81% 9.09% 0.70x 1.53x $-4.49 Million
2022 12.37% 10.99% 0.73x 1.54x $4.52 Billion
2023 19.51% 18.33% 0.76x 1.39x $21.97 Billion
2024 19.85% 19.95% 0.72x 1.38x $27.63 Billion
2025 16.96% 17.37% 0.66x 1.48x $23.21 Billion

Industry Comparison

This section compares Dr. Reddy’s Laboratories Ltd ADR's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $459,373,250
  • Average return on equity (ROE) among peers: -63.25%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Dr. Reddy’s Laboratories Ltd ADR (RDY) $362.08 Billion 13.86% 0.50x $11.16 Billion
Aurora Cannabis Inc (ACB) $605.09 Million 0.26% 0.40x $197.35 Million
Akanda Corp (AKAN) $26.90 Million -43.34% 0.45x $1.51 Million
Akebia Ther (AKBA) $74.01 Million -330.87% 6.15x $340.21 Million
Alkermes Plc (ALKS) $1.82 Billion 13.28% 0.39x $4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX) $164.76 Million -183.14% 0.18x $1.77 Billion
Amphastar P (AMPH) $337.33 Million 1.34% 0.35x $959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $366.97 Million 2.90% 9.74x $3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $896.36 Million -18.93% 3.86x $3.57 Billion
Anika Therapeutics Inc (ANIK) $287.08 Million 1.44% 0.21x $199.00 Million
ANI Pharmaceuticals Inc (ANIP) $15.92 Million -75.48% 0.12x $1.80 Billion

About Dr. Reddy’s Laboratories Ltd ADR

NYSE:RDY USA Drug Manufacturers - Specialty & Generic
Market Cap
$11.31 Billion
Market Cap Rank
#2064 Global
#751 in USA
Share Price
$13.58
Change (1 day)
+5.76%
52-Week Range
$12.77 - $16.17
All Time High
$16.84
Categories
Companies in USA Drug Manufacturers - Specialty & Generic
About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more